Results 51 to 60 of about 7,297 (209)

The Diagnostic Value of Mean Apparent Propagator‐MRI in Dysthyroid Optic Neuropathy: A Quantitative Analysis of the Entire Visual Pathway

CNS Neuroscience &Therapeutics, Volume 32, Issue 2, February 2026.
The diagnostic model combining orbital and intracranial MAP‐MRI parameters could significantly optimize diagnostic efficiency of dysthyroid optic neuropathy. Comprehensive MAP‐MRI parameters analysis of the entire visual pathway enables a deeper understanding of disease involvement, provides novel insights into the early accurate diagnosis and ...
Mengsha Zou, Dide Wu, Yanglei Cheng, Haodong Qin, Zhiyun Yang, Shubin Hong, Hongzhang Zhu, Cui Yan   +7 more
wiley   +1 more source

Increased percentage of L-selectin+ and ICAM-1+ peripheral blood CD4+/CD8+ T cells in active Graves' ophthalmopathy. [PDF]

, 2009
The purpose of the study was to evaluate the percentage of CD4+/CD8+ peripheral T cells expressing CD62L+ and CD54+ in patients with Graves' disease and to assess if these estimations could be helpful as markers of active ophthalmopathy.
A Bossowski, A De Bellis, A Heufelder, A Kretowski, A Modelska-Ziolkiewicz, A Pappa, A Pappa, Alina Bakunowicz-Lazarczyk, Anna Stasiak-Barmuta, G Foerster, G Kulig, G Liu, I Wakelkamp, I Wakelkamp, J Aniszewski, J Mysliwiec, Janusz Mysliwiec, L Bartalena, M Kazim, Maria Gorska, N Xia, P Boulos, Przemysław Pawlowski, R Bahn, S Yan, W Wiersinga   +25 more
core   +3 more sources

Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization

Laryngoscope Investigative Otolaryngology, Volume 11, Issue 1, February 2026.
Teprotumumab has been proven effective in thyroid eye disease and associated exophthalmos management. Since its FDA approval in 2020, teprotumumab therapy has been a popular choice for managing exophthalmos which has resulted in decreased utilization of orbital decompression surgery, from 36.8% between 2015 and 2020 to 11.1% TED patients between 2020 ...
Nitish Kumar, Pedro Lança Gomes, Gaurav Jategaonkar, Michael J. Marino, Amar Miglani, Devyani Lal   +5 more
wiley   +1 more source

Dry eye syndrome in thyroid-associated ophthalmopathy

Oftalʹmologiâ, 2015
Purpose: The pathogenesis of keratoconjunctivitis sicca in patients with thyroid eye disease is presented. The influence of therapy by a HYLO-PARIN® on a condition of a tear film in patients with various forms of thyroid eye disease is assessed. Methods:
A. F. Brovkina, O. N. Steshenko, O. D. Zhukova   +2 more
doaj   +3 more sources

Thyroid-Associated Ophthalmopathy after Radioactive Iodine Therapy for Metastatic Follicular Thyroid Carcinoma

Case Reports in Endocrinology, 2021
Thyroid-associated ophthalmopathy (TAO) is an inflammation of the extraocular muscles and periorbital connective tissue caused by autoantibodies against common antigens to both the thyroid and orbit.
Daisuke Murayama, Soji Toda, Yoichiro Okubo, Hiroyuki Hayashi, Ai Matsui, Mio Yasukawa, Hiroyuki Iwasaki   +6 more
doaj   +1 more source

Microbiome in orbital fat under thyroid associated ophthalmopathy

Medicine in Microecology, 2022
Thyroid associated ophthalmopathy (TAO) manifests as orbital adipose hyperplasia, leading to high intraocular pressure, severe pain, and blindness. The underlying factors that trigger the abnormal immune process in TAO remain unknown.
Yang Li, Fei Wang, Zhijia Hou, Zihan Nie, Lan Ma, Shiqi Hui, Dongmei Li   +6 more
doaj   +1 more source

Active Moderate-to-Severe Graves' Orbitopathy in a Patient With Type 2 Diabetes Mellitus and Vascular Complications [PDF]

, 2019
Background: Graves’ orbitopathy (GO) is the main extrathyroidal manifestation of Graves’ disease (GD). Diabetes mellitus (DM) has been reported to be a risk factor in patients with GO.
Biondi, B, Liccardi, A, Peschi, L, Pontieri, G, Ruggiero, A R, Urselli, F   +5 more
core   +2 more sources

Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease

Acta Ophthalmologica, Volume 104, Issue 1, Page e28-e38, February 2026.
Abstract Purpose To examine ocular surface changes and inflammatory tear fluid biomarkers in patients with thyroid eye disease (TED). Methods We included 106 Graves' disease (GD) patients (36 without TED, 32 with active and 38 with inactive TED) and 106 age‐ and sex‐matched healthy subjects for ophthalmological evaluation, including ocular surface ...
Mikael Thomassen Neset, Roy Miodini Nilsen, Kristian Løvås, Kathrine Halsøy, Håkon Reikvam, Ann‐Elin Meling Stokland, Grethe Åstrøm Ueland, Anette S. B. Wolff, Hans Christian D. Aass, Sjur Reppe, Eystein Sverre Husebye, Eyvind Rødahl, Tor Paaske Utheim, Hans Olav Ueland   +13 more
wiley   +1 more source

Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management [PDF]

, 2017
INTRODUCTION: Dysthyroid optic neuropathy (DON) is a severe manifestation of thyroid eye disease (TED) that can result in permanent vision loss. Management is complex, multidisciplinary, and involves medical and/or surgical therapies.
Blandford, Alexander D., Chundury, Rao V., Perry, Julian D., Zhang, Dalia   +3 more
core   +1 more source

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition

Advanced Science, Volume 13, Issue 4, 19 January 2026.
This study presents YC3, a novel inhibitory TSHR‐targeting aptamer, as a promising therapeutic for Graves' ophthalmopathy (GO). YC3 suppresses pathological phenotypes in human orbital fibroblasts and improves outcomes in GO mice by binding to a previously unidentified allosteric site on TSHR, demonstrating the potential of aptamers in advancing ...
Yanchen Zhang, Ende Wu, Weibin Liu, Ling Zeng, Neng Ling, Hongmei Wang, Zhixing Li, Shuang Yao, Tonghe Pan, Xuanwen Li, Yate Huang, Xiaojing Li, Yunhai Tu, Wentao Yan, Jianzhang Wu, Mao Ye, Wencan Wu   +16 more
wiley   +1 more source